Related Experiment Video
Updated: Aug 8, 2026
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Design of clinical trials in sepsis: problems and pitfalls
1Department of Microbiology and Infectious Diseases, City Hospital, UK.
Abstract:
The pathophysiology of sepsis has been studied intensively in recent years and a variety of opportunities for therapeutic intervention have been identified. A number of biological products including endotoxin antibodies, cytokine inhibitors and receptor antagonists have been evaluated after the failure of pharmacological doses of steroids to influence survival in septic shock. Despite a number of large, international multi-centre studies, the therapeutic promise of these various interventions remains unfulfilled. These trials have largely been conducted in intensive care units in a heterogeneous population of patients with various entry criteria and end-points of response. While the clinical trial must remain the standard for assessing safety and efficacy of new interventions there are opportunities to improve on the design, execution and analysis of these studies. Factors such as the appropriateness of antibiotic therapy, the adequacy of medical and surgical management, and the issue of withdrawal or withholding of life support are discussed in relation to these studies. Furthermore the role of an independent scientific extramural review committee is stressed, particularly in relation to the impact of confounding events of an unforeseen nature. The potential for improving the quality of the analyses of clinical trials of sepsis is illustrated by a recently completed study of the efficacy of a murine monoclonal antibody to human tumour necrosis factor-alpha.
Insights
Despite extensive research, sepsis treatments like endotoxin antibodies and cytokine inhibitors have failed to improve survival. Improving clinical trial design, execution, and analysis is crucial for developing effective sepsis therapies.
Area of Science:
- Critical care medicine
- Immunology
- Pharmacology
Background:
- Sepsis pathophysiology research has identified therapeutic targets.
- Previous interventions, including steroids, endotoxin antibodies, cytokine inhibitors, and receptor antagonists, have not improved survival in septic shock.
- Large international multi-center studies have yielded unfulfilled therapeutic promise.
Purpose of the Study:
- To review the challenges and opportunities in sepsis clinical trial design, execution, and analysis.
- To discuss factors influencing trial outcomes, such as antibiotic therapy, medical/surgical management, and life support decisions.
- To highlight the importance of independent scientific review for unforeseen confounding events.
Main Methods:
- Review of recent sepsis pathophysiology research and clinical trial outcomes.
- Discussion of critical factors impacting clinical trial validity.
- Illustration using a study of a murine monoclonal antibody to human tumor necrosis factor-alpha.
Main Results:
- Numerous sepsis interventions have failed to demonstrate efficacy in large clinical trials.
- Heterogeneous patient populations, varied entry criteria, and diverse endpoints complicate trial interpretation.
- Factors like antibiotic appropriateness, overall patient management, and life support decisions significantly confound results.
Conclusions:
- Improving sepsis clinical trial design, execution, and analysis is essential for advancing therapeutic development.
- Independent scientific review is vital to mitigate the impact of confounding events.
- Enhanced analytical approaches are needed to accurately assess sepsis intervention efficacy, as demonstrated by trials of tumor necrosis factor-alpha inhibitors.
More Related Videos
10:38Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies
Published on: January 16, 2019
07:30Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
Published on: June 15, 2019
Related Concept Videos
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
01:28Preclinical Development: Overview
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...